Protein Design Labs Inc. decided against further development of Zamyl as an acute myeloid leukemia treatment on news that its Phase III trial failed to show statistical significance. (BioWorld Today)
Protein Design Labs Inc. decided against further development of Zamyl as an acute myeloid leukemia treatment on news that its Phase III trial failed to show statistical significance. (BioWorld Today)